Targeting Ferroptosis With Ginsenoside Rg3 Alleviates Intervertebral Disc Degeneration

Abstract

Objective: Intervertebral disc degeneration (IVDD) has been closely associated with ferroptosis in nucleus pulposus cells (NPCs), the underlying regulatory mechanisms and therapeutic strategies remain poorly defined. This study aims to delineate how ginsenoside Rg3 mitigates IVDD progression through ferroptosis suppression, providing a basis for clinical translation.

Method: An erastin-induced nucleus pulposus cell ferroptosis model was established. Suitable Erastin concentrations (0–20 μM) were screened via CCK-8, qRT-PCR, and Western blotting based on viability, extracellular matrix (COL2A1/ACAN/ADAMTS5/MMP3) and ferroptosis markers (GPX4/FTH-1/ACSL4), followed by determination of optimal Rg3 concentrations (0–150 μM) using identical methods. Key targets of Rg3 were predicted through network pharmacology and verified by qRT-PCR and Western blotting. After establishing a rat tail puncture-induced IVDD model, local injection of Rg3 was administered. Therapeutic efficacy was evaluated by MRI assessment of nucleus pulposus status and disc height, alongside histological and immunohistochemical analyses of Rg3's role in delaying disc degeneration.

Result: 5 μM Erastin effectively induced ferroptosis in nucleus pulposus cells, reducing cell viability, suppressing expression of extracellular matrix anabolic proteins (COL2A1, ACAN), while promoting catabolic factors (MMP3, ADAMTS5) and downregulating ferroptosis inhibitors (GPX4, FTH-1). These alterations were significantly reversed by 100 μM Rg3. Integrated network pharmacology and molecular biological validation identified PRKAA2 as the key target mediating Rg3's anti-degenerative effects. In vivo rat experiments demonstrated that Rg3 treatment preserved disc height and attenuated disc degeneration, with histological and immunohistochemical analyses further confirming its therapeutic efficacy and PRKAA2-targeted regulation.

Conclusion: This study elucidates the therapeutic mechanism of Rg3 in delaying IVDD progression via PRKAA2-mediated ferroptosis inhibition, providing substantial experimental evidence for its clinical translation as a potential disease-modifying agent.

Keywords

ferroptosis / ginsenoside Rg3 / intervertebral disc degeneration / network pharmacology / PRKAA2

References

[1] T. Vos, S. S. Lim, C. Abbafati, et al., “Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019,” Lancet 396 (2020): 1204-1222.

[2] J. Hartvigsen, M. J. Hancock, A. Kongsted, et al., “What Low Back Pain Is and Why We Need to Pay Attention,” Lancet 391 (2018): 2356-2367.

[3] C. S. Han, M. J. Hancock, S. Sharma, et al., “Low Back Pain of Disc, Sacroiliac Joint, or Facet Joint Origin: A Diagnostic Accuracy Systematic Review,” EClinicalMedicine 59 (2023): 101960.

[4] J. Dowdell, M. Erwin, T. Choma, A. Vaccaro, J. Iatridis, and S. K. Cho, “Intervertebral Disk Degeneration and Repair,” Neurosurgery 80 (2017): S46-S54.

[5] S. Sharifi, S. K. Bulstra, D. W. Grijpma, and R. Kuijer, “Treatment of the Degenerated Intervertebral Disc; Closure, Repair and Regeneration of the Annulus Fibrosus,” Journal of Tissue Engineering and Regenerative Medicine 9 (2015): 1120-1132.

[6] T. Benzakour, V. Igoumenou, A. F. Mavrogenis, and A. Benzakour, “Current Concepts for Lumbar Disc Herniation,” International Orthopaedics 43 (2019): 841-851.

[7] S. Yang, F. Zhang, J. Ma, and W. Ding, “Intervertebral Disc Ageing and Degeneration: The Antiapoptotic Effect of Oestrogen,” Ageing Research Reviews 57 (2020): 100978.

[8] V. Francisco, J. Pino, M. Á. González-Gay, et al., “A New Immunometabolic Perspective of Intervertebral Disc Degeneration,” Nature Reviews Rheumatology 18 (2022): 47-60.

[9] S. Chen, P. Fu, H. Wu, and M. Pei, “Meniscus, Articular Cartilage and Nucleus Pulposus: A Comparative Review of Cartilage-Like Tissues in Anatomy, Development and Function,” Cell and Tissue Research 370 (2017): 53-70.

[10] X. Zhou, J. Wang, X. Huang, et al., “Injectable Decellularized Nucleus Pulposus-Based Cell Delivery System for Differentiation of Adipose-Derived Stem Cells and Nucleus Pulposus Regeneration,” Acta Biomaterialia 81 (2018): 115-128.

[11] S. Suzuki, N. Fujita, N. Hosogane, et al., “Excessive Reactive Oxygen Species Are Therapeutic Targets for Intervertebral Disc Degeneration,” Arthritis Research & Therapy 17 (2015): 316.

[12] Y. Wang, H. Cheng, T. Wang, K. Zhang, Y. Zhang, and X. Kang, “Oxidative Stress in Intervertebral Disc Degeneration: Molecular Mechanisms, Pathogenesis and Treatment,” Cell Proliferation 56 (2023): e13448.

[13] B. Peng, J. Hao, S. Hou, et al., “Possible Pathogenesis of Painful Intervertebral Disc Degeneration,” Spine 31 (2006): 560-566.

[14] Y. Xu, X. Xu, R. Chai, and X. Wu, “Targeting Ferroptosis to Enhance the Efficacy of Mesenchymal Stem Cell-Based Treatments for Intervertebral Disc Degeneration,” International Journal of Biological Sciences 21 (2025): 1222-1241.

[15] Y. Wang, L. Tan, W. Zhang, et al., “Injectable Dynamic Hydrogel With Responsive Mechanical Reinforcing Ability Reverses Intervertebral Disc Degeneration by Suppressing Ferroptosis and Restoring Matrix Homeostasis,” Advanced Functional Materials 34 (2024): 2310416.

[16] Y. Liu, Y. Wan, Y. Jiang, L. Zhang, and W. Cheng, “GPX4: The Hub of Lipid Oxidation, Ferroptosis, Disease and Treatment,” Biochimica et Biophysica Acta - Reviews on Cancer 1878 (2023): 188890.

[17] B. Huang, H. Wang, S. Liu, et al., “Palmitoylation-Dependent Regulation of GPX4 Suppresses Ferroptosis,” Nature Communications 16 (2025): 867.

[18] W. Fan, L. Fan, Z. Wang, et al., “Rare Ginsenosides: A Unique Perspective of Ginseng Research,” Journal of Advanced Research 66 (2024): 303-328.

[19] S. Kang, S.-J. Park, A.-Y. Lee, J. Huang, H.-Y. Chung, and D.-S. Im, “Ginsenoside Rg3 Promotes Inflammation Resolution Through M2 Macrophage Polarization,” Journal of Ginseng Research 42 (2018): 68-74.

[20] Y. Shan, J. Li, A. Zhu, W. Kong, R. Ying, and W. Zhu, “Ginsenoside Rg3 Ameliorates Acute Pancreatitis by Activating the NRF2/HO-1-Mediated Ferroptosis Pathway,” International Journal of Molecular Medicine 50 (2022): 89.

[21] X. Zhang, F. Huang, X. Chen, X. Wu, and J. Zhu, “Ginsenoside Rg3 Attenuates Ovariectomy-Induced Osteoporosis via AMPK/mTOR Signaling Pathway,” Drug Development Research 81 (2020): 875-884.

[22] L. Li, Y. Wang, R. Guo, et al., “Ginsenoside Rg3-Loaded, Reactive Oxygen Species-Responsive Polymeric Nanoparticles for Alleviating Myocardial Ischemia-Reperfusion Injury,” Journal of Controlled Release 317 (2020): 259-272.

[23] W. Liu, S.-X. Zhang, B. Ai, et al., “Ginsenoside Rg3 Promotes Cell Growth Through Activation of mTORC1,” Frontiers in Cell and Development Biology 9 (2021): 730309.

[24] J. Chen, B. Zhang, L. Wu, and J. Xu, “Ginsenoside Rg3 Exhibits Anti-Catabolic and Anti-Apoptotic Effects in IL-1β Treatedhuman Disc Nucleus Pulposus Cells and in a Rat Model of Disc Degeneration Byinactivating the MAPK Pathway,” Cellular and Molecular Biology (Noisy-le-Grand, France) 70 (2024): 233-238.

[25] W.-C. Huang, T.-H. Huang, K.-W. Yeh, Y.-L. Chen, S.-C. Shen, and C.-J. Liou, “Ginsenoside Rg3 Ameliorates Allergic Airway Inflammation and Oxidative Stress in Mice,” Journal of Ginseng Research 45 (2021): 654-664.

[26] X. Zhao, Z. Sun, B. Xu, et al., “Degenerated Nucleus Pulposus Cells Derived Exosome Carrying miR-27a-3p Aggravates Intervertebral Disc Degeneration by Inducing M1 Polarization of Macrophages,” Journal of Nanobiotechnology 21 (2023): 317.

[27] H. Wang, Z. Jiang, Z. Pang, T. Zhou, and Y. Gu, “Acacetin Alleviates Inflammation and Matrix Degradation in Nucleus Pulposus Cells and Ameliorates Intervertebral Disc Degeneration In Vivo,” Drug Design, Development and Therapy 14 (2020): 4801-4813.

[28] W.-H. Chen, H.-Y. Liu, W.-C. Lo, et al., “Intervertebral Disc Regeneration in an Ex Vivo Culture System Using Mesenchymal Stem Cells and Platelet-Rich Plasma,” Biomaterials 30 (2009): 5523-5533.

[29] K. Sun, Z. Kang, C. Yan, et al., “Rescuing ACE2-Deficiency-Mediated Nucleus Pulposus Senescence and Intervertebral Disc Degeneration by a Nanotopology-Enhanced RNAi System,” Advanced Science 12, no. 9 (2025): e2412908.

[30] X. Yang and X. Li, “Nucleus Pulposus Tissue Engineering: A Brief Review,” European Spine Journal 18 (2009): 1564-1572.

[31] C. Feng, M. Yang, M. Lan, et al., “ROS: Crucial Intermediators in the Pathogenesis of Intervertebral Disc Degeneration,” Oxidative Medicine and Cellular Longevity 2017 (2017): 5601593.

[32] J. Bai, Y. Zhang, Q. Fan, et al., “Reactive Oxygen Species-Scavenging Scaffold With Rapamycin for Treatment of Intervertebral Disk Degeneration,” Advanced Healthcare Materials 9 (2020): 1901186.

[33] Y. Dou, X. Sun, X. Ma, X. Zhao, and Q. Yang, “Intervertebral Disk Degeneration: The Microenvironment and Tissue Engineering Strategies,” Frontiers in Bioengineering and Biotechnology 9 (2021): 118, https://doi.org/10.3389/fbioe.2021.592118.

[34] L. Liu, J. He, C. Liu, et al., “Cartilage Intermediate Layer Protein Affects the Progression of Intervertebral Disc Degeneration by Regulating the Extracellular Microenvironment (Review),” International Journal of Molecular Medicine 47 (2021): 475-484.

[35] Y. Xie, R. Kang, D. J. Klionsky, and D. Tang, “GPX4 in Cell Death, Autophagy, and Disease,” Autophagy 19 (2023): 2621-2638.

[36] S. Park, M. J. Park, E.-J. Kwon, et al., “The Protective Role of GPX4 in Naïve ESCs Is Highlighted by Induced Ferroptosis Resistance Through GPX4 Expression,” Redox Biology 81 (2025): 103539.

[37] Q. Yang, N. Wang, J. Zhang, et al., “In Vitro and In Silico Evaluation of Stereoselective Effect of Ginsenoside Isomers on Platelet P2Y12 Receptor,” Phytomedicine 64 (2019): 152899.

[38] X. Li, J. Tsauo, C. Geng, H. Zhao, X. Lei, and X. Li, “Ginsenoside Rg3 Decreases NHE1 Expression via Inhibiting EGF-EGFR-ERK1/2-HIF-1α Pathway in Hepatocellular Carcinoma: A Novel Antitumor Mechanism,” American Journal of Chinese Medicine 46 (2018): 1915-1931.

[39] Y. Gao, J. Yan, J. Li, et al., “Ginsenoside Rg3 Ameliorates Acetaminophen-Induced Hepatotoxicity by Suppressing Inflammation and Oxidative Stress,” Journal of Pharmacy and Pharmacology 73 (2021): 322-331.

[40] X. Zhang, F. Huang, J. Liu, Z. Zhou, S. Yuan, and H. Jiang, “Molecular Mechanism of Ginsenoside Rg3 Alleviation in Osteoporosis via Modulation of KPNA2 and the NF-κB Signalling Pathway,” Clinical and Experimental Pharmacology and Physiology 52 (2025): e70019.

RIGHTS & PERMISSIONS

2025 The Author(s). Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.